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Vecdne or immunotherapeutic-induced immunity sufficbnt to pmtect from info+ tion end/or diaeaae baa been observed in NHP model studies. Such pmclinical efficacy studies are helping to define important immunological milestones for the measumment and evaluation of vaKiRe candfdates in cknicat trials~ The number of pmchtcal examples of pmtection from infection and diseasefss~*btthese~them has bean considerable debate concerning which arm of the immune system nppears to be more important in elititing the type of pmtectfon observed The foltowtng summary highlights the dfscussions that aross at the ~kshop during the intemomparison of studies of natural and aqufmd immunity and portrays the emetging trends, while emphasis@ current questions that remain to be sddressod in future stud& @ox 2). Fibrally, cases of transient infection finfection with subsequent clearance) were considered. Three types of immune reactlvities were observed in high seronegative, transiently expressed, virus-isolation-positive patienkantiCWantibodies,anti-HLAantibodies and Th-type responses to envelope peptides. Furthermore, higher prevalences of sp&fic MHC transporter associated with antigen processing U$l variants, and CD8' cells that expressed CD25' antigen were apparent in these individuals (Mann).
Rrxent findings report tlrat some uninfected indivtduals with a high risk of HIV-l infection are homozygous for a 3%base-pair deletion of their CC-CKR-5 genes UXtXlX~ 5~32P'! This cults in a loss of extracellular expression of this rewptor.
Protection from approximately 5% of infect& individuals remain healthy without evidcnm of d&se pmgte~sion. Infcvtion with attenuahd virus is&k% is documented in very ram cases, but for the majority of long-term survivors (LTSsl or LTNPsJ !his appears not to be the case. Some infeuted individuals with slow disease progression are heterozygous for CCCKR-5632 (Ref. 19) . In studies of n&tame to disease, seropositive rapid progressors (RI%) am often complnd with LTNPS. Central to the discussion of the host's susceptibility or resistance to disease is the immune mgulrtory function of the MHC. In humans, ceeain MHC class I alleles when associated Iates may be obtained, and to which region 9 of the HIV-1 envclepc these should bc c dirertd. Vaccination with envelope-bscc i vaccinr~~ induces neutralizing antibodies tc D both linear and discontinuous epitqes pri imadly within the V2 and V3 regions. Th' C use of truncated forms may broadel n immunity to include VW2 regions, IF L sponses that correlate with neutralizing titr e and crossreactive neutralizing response 19 in rodents fJ. McKeating, Reading). FUI rthermom the state of activation of the targc :t cell appears to have a significant effect o n the efficacy of neutralizing antibodies !(I (S. Zolla-Pazner, New York, NW. S-L. Hu &attle, WA) discussed current vaccine strategies: 'priming with recombinant viruses that express HIV1 for SIV) enu folhwed by subunit boosting appears to be me of the most effective ways of achieving protection from cell-free i.v. challenge. In the SIVmne model, vaccination with gcg-pal alone showed that env was a necessary component for vatine protection from infection; however, subunit euo alone was not sutlicient for protection despite simiir levels of neutralizing antibodies being achieved. There remains considerable debate concerning whether true sterilizing immunity was achieved, or whether limited virus replication occurted before infected cells and virions werecleared.
No immunological conelate of protection was found in vaccinated chimpanzees challenged i.v. with infected blood mononuclear cells from another HIV-l-infected chimpanzee. In a similar study, vaccinated rhesus monkeys were found to be protected --: I .,.
Several studies pointed to the possible benefit of vaccination or immunotherapy to reduce virus load and possibly to slow or halt progression of disease. Studies in HIV-l-canvaccinated chimpanzees have shown that in the case of infection, virus load can be significantly mducedrr. In addition, in the SlVmne model, although gng and pl alone am insufficient for inducing sterilizing immunity, they were shown to be effective in mducing virus load (Hu). Furthermore, vaccination of rhesus monkeys with vaccinia recombinants containing only SNmac rrcf resulted in a beneficial effect in reducing virus load that inversely correlated with CTLprecursor frequency (F. Gotch, London)39 Another appmach using a ucf-defective SIVmac strain of live attenuated vaccine in rhesus monkeys, revealed that recipients challenged with wild-type SlVmac were resistant to infection with the challenge strain. By contrast to non-vaccinated SlVmacinfected controls, vaccinees maintained Thcell responses (G. Hunsmann, Giittingen). Although aone of these studies reached a clinical endpoint, these data suggest that a beneficial effect in humans may be achieved since virus load is an important marker of disease progression.
The role of antibodies was also examined. Broad cross-neutralizing antibody titres were shown to be associated with slow disease progression and low risk of transmission in HIV-Z-infruted macaques (E-M. Fenyo, Stockholm). The mle of antibodies in slowing disease progression was elegantly demonstrated in an SIV model: in cases whete SIV-immunoglobulin was administered shortly after experimental SIV infecBon i,v., recipients maintained lower virus lands and survived longer thnn untrentcd controls (N. Hal&wood, Seattlc, WA).
Emerging trends
Accumulnting numbers of reports suggest that repeated sub-Infectious low-dose exposum to HIV may elicit protective Immunity, However, this observation needs rlgorous evaluation to differentiate between: (1) individuals that have an existing natural resistance to infection and those thai have acquired immunity by exposure; and (2) Individuals that have acquired immunity and are truly uninfected and those that have a cryptic low-level or local infection. Cases of reported clearance of viral infection are of considerable importance; these cases need to be well documented and the immune responses as well as the virology require careful long-term follow-up.
It is apparent that the disease course may be established or greatly influenced by events immediately post-infection, which establish virus-load levels either before or after seroconversion. Current data suggest that in order to prolong survival, effective pm-existing or acquired immunity in this early period is very important. Passive immunity may be effective in this context, but must be established in a manner that will protect the immunological infrastructure from immunosuppressive effects of the virus and that allows effective de aauo hostimmune responses. Effective CTL responses to multiple epitopes may be important for reducing cell-associated virus load early after infection. If infection is not resolved to a low level, CTLs may possibly contribute to the immunopathogenesis of the disease. The roles of CDS-suppressor factors and HIV-inhibitory chemokines in protective immunity and the pathogenic process itr vizn am now in need of elucidation. Protective immunity in the presence of HIV-l infection appears to depend on intact Th responses thnt are responsible for primary cellular as well as humoral responses. Current trends suggest that vaccines intended for pmtection from HIV infection must be able to induce host responses that effectively limit extracellular viremia and effect clearance of virus-infected cells, while promoting primary host responses to new viral epitopes.
Ca avior avafawa and Frank Eggert he mnjor histocompatibility complex (MI-ICI has been the subject of study for sever,4 decades. Much interest has focuscd on Its regulation of the immune rvsponse, and most immunologists nnd biologists consider the function of the MHC to lie in immune defense. MHC polymorphism appears clearly to favor this simplistic view but, from nn evolutionary point of view, the MHC hns a much bmder and univcr4 fUtV3km. The use Of tIIOJe&aP genetic hvhniques has recently led to the discovery of even more new genes within the MHC. In mice, 58 nonclassical MHC cless I gcncs, pseudogenes nnd gene fmgmenh hnve been idcntificd. Their role is not yet understcad, but their lack of polymorphism suggests thnt they possess more-gencmlized functions, if any. In addition, olfsctory.~ptor-like genes have been rrmntly described in the humen and mouse class I mgions.
The mirjor feature of the MHC is its extmordinary genetic diversity, which seems t0 bc selectively mrrint&ed in contempowry natural populations, although the strength and natureof thissel&ion ~mcurrently unclar'. B+csuse of the critical mle played by proteins cnmded by the MHC in immune nXognition, it is gencmlly assumed that Same formaf ~msite-drivcn seIection takes place*. However, the high dgrec of hetero. zygosity found in nntural populations 01 most spe2ics sexms to be promoted by non disease-based selection, such RY mnting pmfemnm and selective block of pn3nanc-y Lewis Thomas was the first to speyulntc that the MHC might play n mlc in socinl be havior ns an expression of genctlc lndividu Sty, but he failed to explain how ond wh! it mny be involved. 
